Can you use structured experiments to solve intractable problems and create novel products?
Trying new things is foundational to innovation. If you work for an organization that is establishing new products or processes; or in an industry characterized by speed, precision or stiff competition; then you may have heard of design of experiments (DOE). With DOE, we actively manipulate factors according to a prespecified plan to gain useful, new understanding of relationships among the inputs and outputs. DOE allows us to make better use of existing data, solve problems we couldn’t solve before, improve our decision making and innovate. The methodology also leads us to new questions we should explore.
George Box once said, “Discovering the unexpected is more important than confirming the known.” And non-intuitive findings and efficiencies gained using DOE can give you a significant competitive advantage.
Join us for keynote talks and a panel discussion where we’ll simplify the term DOE, turning it from overwhelming to imperative. Our speakers passionately advocate for every engineer and scientist to adopt DOE as an essential tool for efficient, effective discovery of practical insights. Attend and you’ll learn the power of DOE to speed innovation; achieve faster, more predictable cycles; and save time. You’ll also hear real-world DOE case studies from prominent organizations that have a lot to share about their successes and challenges implementing a structured approach to experimentation.
Date: 14 October 2021
Time: 10:30 – 12:00 CEST
Venue: Online
Keynotes
 |
Julia O’Neill Distinguished Fellow, CMC Modeling & Statistics Lead, Moderna
Julia O’Neill has over 30 years of experience bridging statistics and chemical engineering in vaccines, biologics, pharmaceutical and chemical development and manufacturing. Her current areas of focus include statistical, validation and regulatory strategy support for a broad range of novel accelerated products, including multiple breakthrough designation and orphan drugs. She has a passion for applying statistical thinking to more rapidly establish the evidence needed to bring forward medicines addressing unmet medical needs. O’Neill has worked at Merck, Rohm and Haas and various analytics consultancies.
|
 |
Dame Sally Davies Executive Chair, The Trinity Challenge
Dame Sally Davies is the Master of Trinity College, Cambridge, and formerly the Chief Medical Officer for England, and the Chief Medical Adviser to the UK Government from 2011 to 2019. In July 2020, she established The Trinity Challenge, a new, global health non-profit, which has brought 42 of the world’s preeminent institutions together as a coalition to surface solutions that will help us identify, respond to, and recover from the next pandemic. She was a member of the WHO Executive Board from 2014 to 2016 and has led delegations to a range of WHO summits and forums since 2004. |